Preview

Безопасность и риск фармакотерапии

Расширенный поиск

ОБЗОР СЛУЧАЕВ РАЗВИТИЯ ОСТРОЙ ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТИ ВСЛЕДСТВИЕ ПРИЕМА БИОЛОГИЧЕСКИ АКТИВНЫХ ДОБАВОК

https://doi.org/10.30895/2312-7821-2018-6-2-68-77

Полный текст:

Аннотация

Во всем мире распространено применение биологически активных добавок, которые общедоступны и могут быть приобретены без консультации с лечащим врачом. Считается, что более 50 % взрослого населения во всем мире используют биологически активные добавки. В статье рассмотрены вопросы регламентации рынка биологически активных добавок во всем мире, в том числе Российской Федерации, безопасность применения, развитие нежелательных реакций. Проведен поиск информации по базам данных о развитии лекарственных повреждений печени, связанных с применением биологически активных добавок, содержащих экстракт зеленого чая, усниновую кислоту, 1,3-диметиламиламин, витамин А, анаболические андрогенные стероиды, линолевую кислоту, эфедру, гарцинию камбоджу, используемых для снижения веса. При применении анаболических стероидов выявлен повышенный риск развития нежелательных реакций со стороны печени, сердечно-сосудистой и эндокринной систем. Применение БАД, содержащих экстракт зеленого чая, может привести к тяжелому поражению печени. Анализ нежелательных реакций после применения БАД под торговым названием Гербалайф выявил случаи фальсификации препаратов. Применение препаратов, содержащих витамин А в высоких дозах, эфедру, гарцинию камбоджу приводило к повышению печеночных трансаминаз, психических расстройств, остеопорозу, анорексии.

Об авторах

М. Л. Максимов
Казанская государственная медицинская академия — филиал федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации; 2 Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
Россия

Максимов Максим Леонидович. Заведующий кафедрой клинической фармакологии и фармакотерапии КГМА;  ведущий аналитик отдела методологии экспертного анализа Управления экспертизы безопасности лекарственных средств ФГБУ «НЦЭСМП». доктор медицинских наук. профессор 

ул. Муштари, д. 11, г. Казань, 420012



С. А. Симакова
Казанская государственная медицинская академия — филиал федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации
Россия

Симакова Светлана Алексеевна. Ассистент кафедры клинической фармакологии и фармакотерапии. 

ул. Муштари, д. 11, г. Казань, 420012



Список литературы

1. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: Data from the National Health and Nutrition Examination Survey: 1999–2000. Am. J. Epidemiol. 2004; 160: 339–49.

2. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, et al. Dietary supplement use in the United States: 2003–2006. J. Nutr. 2011; 141: 261–6. DOI: 10.3945/jn.110.133025

3. Garcia-Alvarez A, Egan B, de Klein S, Dima L, Maggi FM, et al. Usage of plant food supplements across six European countries: Findings from the PlantLIBRA consumer survey. PLoSONE. 2014; 9: 537.

4. Serafini M, Stanzione A, Foddai S, Anton R, Delmulle L. The European role on traditional herbal medicinal products and traditional plant food supplements. J. Clin. Gastroenterol. 2012; 46: S93–4.

5. European Medicines Agency Committee on Herbal Medicinal Products (HMPC) [(accessed on 13 January 2014)]. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_con-tent_000264.jsp

6. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512–21.

7. García-Cortés M, Borraz Y, Lucena MI, Peláez G, Salmerón J, et al. Liver injury induced by “natural remedies”: An analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev. Esp. Enferm. Dig. 2008; 100: 688–95.

8. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419–25. DOI: 10.1053/j.gastro.2013.02.006

9. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399–408. DOI: 10.1002/hep.27317

10. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012; 107: 1380–7.

11. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int. 2007; 27: 465–74.

12. Zhou Y, Yang L, Liao Z, He X, Guo H. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol. 2013; 25: 825–9.

13. Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. Liver Int. 2011; 31: 595–605.

14. Commission on Dietary Supplement Labels Chapter I Dietary Supplement Health And Education Act of 1994. [(accessed on 13 January 2014)]; Available online: http://www.health.gov/dietsupp/ch1.htm.

15. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993; 46: 1323–30.

16. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399–408.

17. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, García-Cortes M, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment. Pharmacol. Ther. 2015.

18. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin. Liver Dis. 1981; 1: 116–28.

19. Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, et al. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J. Clin. Gastroenterol. 2009.

20. Timcheh-Hariri A, Balali-Mood M, Aryan E, Sadeghi M, Riahi-Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem. Toxicol. 2012.

21. Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J. Clin. Gastroenterol. 2009.

22. Turani H, Levi J, Zevin D, Kessler E. Hepatic lesions in patients on anabolic androgenic therapy. Isr. J. Med. Sci. 1983.

23. Patil JJ, O’Donohoe B, Loyden CF, Shanahan D. Near-fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: A case report. Br. J. Sports Med. 2007.

24. Agbenyefia P, Arnold CA, Kirkpatrick R. Cholestatic Jaundice With the Use of Methylstenbolone and Dymethazine, Designer Steroids Found in Super DMZ Rx 2.0 “Nutritional Supplement” A Case Report III. J. Investig. Med. High Impact Case Rep. 2014.

25. Hymel BM, Victor DW, Alvarez L, Shores NJ, Balart LA. Mastabol induced acute cholestasis: A case report. World J. Hepatol. 2013.

26. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 1987.

27. Brazeau MJ, Castaneda JL, Huitron SS, Wang J. A Case Report of Supplement-Induced Hepatitis in an Active Duty Service Member. Mil. Med. 2015.

28. Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008.

29. Gavilan JC, Bermudez FJ, Salgado F, Pena D. Phytotherapy and hepatitis. Rev. Clin. Esp. 1999; 199: 693–4.

30. Pillukat MH, Bester C, Hensel A, Lechtenberg M, Petereit F, et al. Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman. A case report with pharmaceutical analysis. J. Ethnopharmacol. 2014; 155: 165–70.

31. Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, et al. Acute liver failure induced by green tea extracts: Case report and review of the literature. Liver Transpl. 2006; 12: 1892–5.

32. Verhelst X, Burvenich P, Van Sassenbroeck D, Gabriel C, Lootens M, Baert D. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia sinensis) Acta Gastroenterol. Belg. 2009; 72: 262–4.

33. Patel SS, Beer S, Kearney DL, Phillips G, Carter BA. Green tea extract: A potential cause of acute liver failure. World J. Gastroenterol. 2013; 19: 5174–7.

34. Lorenzo-Almorós A, Polo-Sabau J, Barrio-Dorado MP, Ruggiero GM. Acute liver injury induced by green tea extracts. Gastroenterol. Hepatol. 2015; 38: 44–5.

35. Bjornsson E, Olsson R. Serious adverse liver reactions associated with herbal weight-loss supplements. J. Hepatol. 2007; 47: 295–7.

36. Abu el Wafa Y, Benavente Fernández A, Talavera Fabuel A, Pérez Ramos MA, Ramos-Clemente JI. Acute hepatitis induced by Camellia sinensis (green tea) An. Med. Interna. 2005; 22: 298.

37. García-Morán S, Sáez-Royuela F, Gento E, López Morante A, Arias L. Acute hepatitis associated with Camellia thea and Orthosiphon stamineusingestión. Gastroenterol. Hepatol. 2004; 27: 559–60.

38. Dueñas Sadornil C, Fabregas Puigtió S, Durández R. Hepatotoxicity due to Camelia sinensis. Med. Clin. 2004; 122: 677–8.

39. Thiolet C, Mennecier D, Bredin C, Moulin O, Rimlinger H, et al. Acute cytolysis induced by Chinese tea. Gastroenterol. Clin. Biol. 2002; 26: 939–40.

40. Weinstein DH, Twaddell WS, Raufman JP, Philosophe B, Mindikoglu AL. SlimQuick™-associated hepatotoxicity in a woman with α-1 antitrypsin heterozygosity. World J. Hepatol. 2012; 4: 154–7.

41. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, et al. Safety of green tea extracts. A systematic review by the US pharmacopeia. Drug Saf. 2008; 31: 469–84.

42. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009; 65: 331–41.

43. Galati G, Lin A, Sultan AM, O’Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med. 2006; 40: 570–80.

44. Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur. J. Gastroenterol. Hepatol. 2005; 17: 1135–7.

45. Pedrós C, Cereza G, García N, Laporte JR. Liver toxicity of Camellia sinensis dried etanolic extract. Med. Clin. 2003; 121: 598–9.

46. Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: First case report. Dig. Dis. Sci. 2009; 54: 1141–3.

47. Nortadas R, Barata J. Fulminant hepatitis during self-medication with conjugated linoleic acid. Ann Hepatol. 2012; 11: 265–7.

48. Bilal M, Patel Y, Burkitt M, Babich M. Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature. Case Rep. Hepatol. 2015.

49. Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J. Hepatol. 2004; 41: 1062–4.

50. Herbalife. [(accesed on 9 January 2016)]. Available online: http://ir.herbalife.com/releasedetail.cfm?ReleaseID=891717.

51. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J. Hepatol. 2007; 47: 521–6.

52. Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J. Hepatol. 2007; 47: 514–20.

53. Duque JM, Ferreiro J, Salgueiro E, Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med. Clin. 2007; 128: 238–9.

54. Manso G, López-Rivas L, Duque JM, Salgueiro E. Испанские сообщения о гепатотоксичности, связанной с продуктами Гербалайф. J. Hepatol. 2008; 49: 289–90. DOI: 10.1016/j.jhep.2008.05.007

55. Manso G, López-Rivas L, Duque JM, Salgueiro E. Spanish reports of hepatotoxicity associated with Herbalife products. J. Hepatol. 2008; 49: 289–90.

56. Chao S, Anders M, Turbay M, Olaiz E, McCormack L, Mastai R. Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol. Latinoam. 2008; 38: 274–7.

57. Chen GC, Ramanathan VS, Law D, Funchine P, Chen GC, et al. Acute liver injury induced by weight-loss herbal supplements. World J. Hepatol. 2010; 2: 410-5. DOI: 10.4254/wjh.v2.i11.410

58. Mengual-Moreno E, Lizarzábal-García M, RuizSoler M, Silva-Suarez N, Andrade-Bellido R, et al. Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela. Investig. Clin. 2015; 56: 3–12.

59. Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 2009; 50: 111–7.

60. Olson JA. Vitamin A. In: Ziegler EE, Filer LJ Jr, eds. Present Knowledge in Nutrition. 7th ed. International Life Sciences Institute; Washington, DC, USA: 2001.

61. Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am. J. Clin. Nutr. 1990; 52: 183–202.

62. Penniston KL, Tanumihardjo SA. The acute and chronic effects of vitamin A. Am. J. Clin. Nutr. 2006; 83: 191–201.

63. Carpenter TO, Pettifor JM, Russell RM, Pitha J, Mobarhan S, et al. Severe hypervitaminosis A in siblings: Evidence of variable tolerance to retinol intake. J. Pediatr. 1987; 111: 507–12. DOI: 10.1016/S0022-3476(87)80109-9

64. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: Estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991; 100: 1701–9.

65. Ramanathan VS, Hensley G, French S, Eysselein V, Chung D, et al. Hypervitaminosis A inducing intra-hepatic cholestasis. A rare case report. Exp. Mol. Pathol. 2010; 88: 324–5. DOI: 10.1016/j.yexmp.2009.11.007

66. Becker P, Maurer B, Schirmacher P, Waldherr R, Parlesak A, et al. Vitamin A induced cholestatic hepatitis: A case report. Z Gastroenterol. 2007; 45: 1063–6. DOI: 10.1055/s-2007-963342

67. Kowalski TE, Falestiny M, Furth E, Malet PF. Vitamin A hepatotoxicity: A cautionary note regarding 25,000 IU supplements. Am. J. Med. 1994; 97: 523–8. DOI: 10.1016/00029343(94)90347-6

68. Croquet V, Pilette C, Lespine A, Vuillemin E, Rousselet MC, et al. Hepatic hyper-vitaminosis A: Importance of retinyl ester level determination. Eur. J. Gastroenterol. Hepatol. 2000; 12: 361–4. DOI: 10.1097/00042737-200012030-00016

69. Nollevaux MC, Guiot Y, Horsmans Y, Leclercq I, Rahier J, et al. Hypervitaminosis A-induced liver fibrosis: Stellate cell activation and daily dose consumption. Liver Int. 2006; 26: 182–6. DOI: 10.1111/j.1478-3231.2005.01207.x

70. Muenter MD, Perry HO, Ludwig J. Chronic vitamin A intoxication in adults. Hepatic, neurologic and dermatologic complications. Am. J. Med. 1971; 50: 129–36. DOI: 10.1016/0002-9343(71)90212-9.

71. Russell RM, Boyer JL, Bagheri SA, Hruban Z. Hepatic injury from chronic hypervitaminosis a resulting in portal hypertension and ascites. N. Engl. J. Med. 1974; 291: 435–40. DOI: 10.1056/NEJM197408292910903

72. Jacques EA, Buschmann RJ, Layden TJ. The histopathologic progression of vitamin A-induced hepatic injury. Gastroenterology. 1979; 76: 599–602.

73. Herbert V. Will questionable nutrition overwhelm nutrition science? Am. J. Clin. Nutr. 1981; 34: 2848–53.

74. Farris WA, Erdman JW. Protracted hypervitaminosis A following long-term, low-level intake. J. Am. Med. Assoc. 1982; 247: 1317. DOI: 10.1001/jama.1982.03320340071041

75. Weber FL, Mitchell GE, Powell DE, Reiser BJ, Banwell JG. Reversible hepatotoxicity associated with hepatic vitamin A accumulation in a protein-deficient patient. Gastroenterology. 1982; 82: 118–23.

76. Hatoff DE, Gertler SL, Miyai K, Parker BA, Weiss JB. Hypervitaminosis A unmasked by acute viral hepatitis. Gastroenterology. 1982; 82: 124–8.

77. Park HM, Ransburg R, Roth C, Meadows J. Scintigraphic dissociation of reticuloendothelial and hepatocyte function in chronic vitamin A hepatotoxicity. Clin. Nucl. Med. 1985; 10: 364–6.

78. Inkeles SB, Connor WE, Illingworth DR. Hepatic and dermatologic manifestations of chronic hypervitaminosis A in adults. Report of two cases. Am. J. Med. 1986; 80: 491–6.

79. Vincent LM. Scintigraphic dissociation of reticuloendothelial and hepatocyte function in chronic vitamin A hepatotoxicity. Clin. Nucl. Med. 1986; 11: 67.

80. Witzleben CL. Case 5. Vitamin A hepatotoxicity. Pediatr. Pathol. 1986; 6: 481–4.

81. Krasinski SD, Russell RM, Otradovec CL, Sadowski JA, Hartz SC, et al. Relationship of vitamin A and vitamin E intake to fasting plasma retinol, retinol-binding protein, retinyl esters, carotene, alpha-tocopherol, and cholesterol among elderly people and young adults: Increased plasma retinyl esters among vitamin A-supplement users. Am. J. Clin. Nutr. 1989; 49: 112–20.

82. Corey R, Werner KT, Singer A, Moss A, Smith M, Noelting J, Rakela J. Acute liver failure associated with Garcinia cambogia use. Ann. Hepatol. 2015; 15: 123–6.

83. Melendez-Rosado J, Snipelisky D, Matcha G, Stancampiano F. Acute hepatitis induced by pure Garcinia cambogia. J. Clin. Gastroenterol. 2015; 49: 449–50.

84. Олефир ЮВ, Медуницын НВ, Авдеева ЖИ, Солдатов АА, Мовсесянц АА, и др. Современные биологические/биотехнологические лекарственные препараты. Актуальные вопросы разработки и перспективы использования. БИОпрепараты. Профилактика, диагностика, лечение 2016; 16(2): 67–77.

85. .Бурова ЕД, Ходько СВ, Гущина СВ, Макарова МН, Макарова ВГ. Управление рисками для обеспечения качества доклинических исследований лекарственных средств. ведомости Научного центра экспертизы средств медицинского применения 2017; 7 (1): 25–32. .


Для цитирования:


Максимов М.Л., Симакова С.А. ОБЗОР СЛУЧАЕВ РАЗВИТИЯ ОСТРОЙ ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТИ ВСЛЕДСТВИЕ ПРИЕМА БИОЛОГИЧЕСКИ АКТИВНЫХ ДОБАВОК. Безопасность и риск фармакотерапии. 2018;6(2):68-77. https://doi.org/10.30895/2312-7821-2018-6-2-68-77

For citation:


Maksimov M.L., Simakova S.A. A REVIEW OF CASES OF DEVELOPMENT OF ACUTE HEPATIC INSUFFICIENCY DUE TO THE INTAKE OF BIOLOGICALLY ACTIVE ADDITIVES. Safety and Risk of Pharmacotherapy. 2018;6(2):68-77. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-2-68-77

Просмотров: 197


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)